Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes.
作者信息
Krumholz Harlan M
出版信息
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):457-9. doi: 10.1161/CIRCOUTCOMES.115.002245.
Abstract
摘要
相似文献
1
Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes.
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):457-9. doi: 10.1161/CIRCOUTCOMES.115.002245.
2
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.
J Am Heart Assoc. 2017 Mar 21;6(3):e005285. doi: 10.1161/JAHA.116.005285.
3
Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.
Am J Cardiol. 2016 Jun 1;117(11):1845-50. doi: 10.1016/j.amjcard.2016.03.021. Epub 2016 Mar 19.
4
Surrogate endpoints: the debate goes on.
Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):493-6. doi: 10.1002/pds.655.
5
Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease.
Clin Pharmacol Ther. 2015 Jul;98(1):12-5. doi: 10.1002/cpt.129. Epub 2015 May 19.
6
Ultrasound and radiology surrogate endpoints in pharmacological studies.
Atherosclerosis. 2012 Sep;224(1):12-24. doi: 10.1016/j.atherosclerosis.2012.03.038. Epub 2012 May 7.
7
Biomarkers and Surrogate Endpoints in Drug Development: A European Regulatory View.
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO27-BIO33. doi: 10.1167/iovs.17-21778.
8
Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges.
Expert Rev Cardiovasc Ther. 2012 Aug;10(8):989-94. doi: 10.1586/erc.12.84.
9
Surrogate endpoints in randomized cardiovascular clinical trials.
Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4.
10
Vascular biomarkers and surrogates in cardiovascular disease.
Circulation. 2006 Jun 27;113(25):2936-42. doi: 10.1161/CIRCULATIONAHA.105.598987.
引用本文的文献
1
Perceived Age as a Mortality and Comorbidity Predictor: A Systematic Review.
Aesthetic Plast Surg. 2023 Feb;47(1):442-454. doi: 10.1007/s00266-022-02932-5. Epub 2022 Jun 1.
2
Advances in Cardiovascular Biomarker Discovery.
Biomedicines. 2020 Nov 30;8(12):552. doi: 10.3390/biomedicines8120552.
3
Does Nonsurgical Periodontal Treatment Improve Systemic Health?
J Dent Res. 2021 Mar;100(3):253-260. doi: 10.1177/0022034520965958. Epub 2020 Oct 22.
4
The Failure to Measure Dietary Intake Engendered a Fictional Discourse on Diet-Disease Relations.
Front Nutr. 2018 Nov 13;5:105. doi: 10.3389/fnut.2018.00105. eCollection 2018.
5
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
BMJ. 2017 May 3;357:j1680. doi: 10.1136/bmj.j1680.
6
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
PLoS Med. 2016 Mar 15;13(3):e1001978. doi: 10.1371/journal.pmed.1001978. eCollection 2016 Mar.
本文引用的文献
1
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.
N Engl J Med. 2015 Jun 4;372(23):2197-206. doi: 10.1056/NEJMoa1414266.
2
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
3
Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT.
N Engl J Med. 2015 Jun 18;372(25):2448-50. doi: 10.1056/NEJMe1507041. Epub 2015 Jun 3.
4
When choosing statin therapy: the case for generics.
JAMA Intern Med. 2013 Feb 11;173(3):229-32. doi: 10.1001/jamainternmed.2013.1529.
5
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
6
Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health.
Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):2-5. doi: 10.1161/CIRCOUTCOMES.111.964676.
7
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15.
8
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
9
Effects of combination lipid therapy in type 2 diabetes mellitus.
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.
10
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.
Zotero 插件